OAM
TVTX icon

Oppenheimer Asset Management’s Travere Therapeutics TVTX Stock Holding History

Oppenheimer Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Buy
+5,320
New +$236K ﹤0.01% 995
2026
Q1 		– Sell
-5,566
Closed -$213K – 1179
2025
Q4 		$213K Buy
+5,566
New +$181K ﹤0.01% 993

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer Asset Management's TVTX Position: Q2 2026 in Review

Oppenheimer Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 5,320 shares worth $302K. The stake represents ﹤0.01% of the portfolio and ranks #995 among its holdings. This is a return to the name: Oppenheimer Asset Management previously reported a position in TVTX as recently as Q4 2025.

Oppenheimer Asset Management first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Oppenheimer Asset Management held 5,320 shares of Travere Therapeutics worth $302K as of Q2 2026.
  • Travere Therapeutics was a new Oppenheimer Asset Management position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #995 holding.
  • Oppenheimer Asset Management first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.